{"id":"mrna-1083","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5868567","moleculeType":null,"molecularWeight":"348.41"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Myostatin is a protein that negatively regulates muscle growth. By inhibiting myostatin, mRNA-1083 aims to increase muscle mass and strength, which can be beneficial in conditions characterized by muscle wasting.","oneSentence":"mRNA-1083 encodes an optimized full-length human myostatin propeptide to inhibit myostatin activity and promote muscle growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:10.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of muscle-wasting diseases such as inclusion body myositis"}]},"trialDetails":[{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT06864143","phase":"PHASE2","title":"A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2","enrollment":1320},{"nctId":"NCT06508320","phase":"PHASE2","title":"A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-07-15","conditions":"Influenza, SARS-CoV-2","enrollment":932},{"nctId":"NCT06097273","phase":"PHASE3","title":"A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-19","conditions":"SARS-CoV-2, Influenza","enrollment":8061}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mRNA-1083","genericName":"mRNA-1083","companyName":"ModernaTX, Inc.","companyId":"modernatx-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"mRNA-1083 encodes an optimized full-length human myostatin propeptide to inhibit myostatin activity and promote muscle growth. Used for Treatment of muscle-wasting diseases such as inclusion body myositis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}